InflaRx N.V. Common Stock (IFRX) Stock
Fundamentals
Compare with IFRX
Recent news

InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline
InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline
IFRX

Week In Review: Kelun-Biotech In $9.5 Billion ADC Deal With Merck
Week In Review: Kelun-Biotech In $9.5 Billion ADC Deal With Merck
IFRX
Technical indicators
- RSI 14
- 26.84
- MACD 12/26/9
- -0.11
- EMA 9 of MACD
- -0.07
- MACD histogram
- -0.04
- SMA 50
- $1.99
- Price below SMA 50
- EMA 50
- $1.96
- Price below EMA 50
- SMA 200
- $1.59
- Price below SMA 200
- EMA 200
- $1.64
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 6, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
Latest news

InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline
InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline
IFRX

Week In Review: Kelun-Biotech In $9.5 Billion ADC Deal With Merck
Week In Review: Kelun-Biotech In $9.5 Billion ADC Deal With Merck
IFRX
About InflaRx N.V. Common Stock
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Prof. Niels C. Riedemann M.D., Ph.D. | Co-Founder, CEO & Executive Director | 1973 |
| Prof. Renfeng Guo M.D. | Co-Founder, Chief Scientific Officer & Executive Director | 1970 |
| Dr. Thomas Taapken Ph.D. | Chief Financial Officer | 1965 |
| Ms. Derval O'Carroll | Senior VP and Global Head of Regulatory Affairs & Compliance | 1966 |
| Mr. Jan Medina CFA | Head of Investor Relations & VP | — |
| Mr. Christian Schmid | VP and Head of Legal Affairs & General Counsel | — |
| Dr. Maria Habel PH.D. | VP, Head of Preclinical R&D and QC | 1982 |
| Mr. Kofi Boaten | VP and Head of Supply Quality & Clinical Trial Supplies | — |
| Mr. Peter Hurt Ph.D. | Senior Director and Head of Drug Safety & Pharmacovigiliance | — |
| Mr. Daniel Vetter | Senior Director & Head of IT | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Technical indicators
- RSI 14
- 26.84
- MACD 12/26/9
- -0.11
- EMA 9 of MACD
- -0.07
- MACD histogram
- -0.04
- SMA 50
- $1.99
- Price below SMA 50
- EMA 50
- $1.96
- Price below EMA 50
- SMA 200
- $1.59
- Price below SMA 200
- EMA 200
- $1.64
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 6, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $6.00
- Average
- $7.00
- High
- $8.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +28.6 | +14.3 | -1.8 | -27.0 | +21.7 | -16.7 | -7.6 |



